Effects of Protein Blends on Muscle Protein Synthesis in Healthy Older Adults

Muscle Synthesis Clinical Trial

Official title:

A Randomized, Controlled Double Blind Acute Study: Effects of Protein Blends on Muscle Protein Synthesis and Breakdown in Healthy Older Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01847261
• Other study ID #: IRB #12-226
• Status: Completed
• Phase: N/A
• Start date: April 2013
• Est. completion date: December 2014

Study information

• Verified date: October 2019
• Source: DuPont Nutrition and Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

During aging there is a tendency for muscle protein synthesis (growth) to become less efficient and the resulting consequence leads to reduced muscle mass (sarcopenia) which can affect strength and mobility. Protein consumption may be one opportunity to alleviate this problem especially when consumed in appropriate amounts following resistance training. This study is designed to determine if a soy dairy protein blend, shown to be effective in younger adults, will produce beneficial muscle protein synthesis in older healthy adults following resistance exercise.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 2014
• Est. primary completion date: November 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 55 Years to 70 Years

Eligibility

Inclusion Criteria:

55-70 yr olds Stable Body weight

Exclusion Criteria:

1. Exercise training (>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)

2. Significant heart, liver, kidney, blood, respiratory disease or thyroid issues

3. Peripheral vascular disease

4. Orthopedic injury that prohibits participation in the exercise training

5. Diabetes mellitus or other untreated endocrine disease

6. Active cancer (all groups) and history of cancer

7. Acute infectious disease or history of chronic infections (e.g. TB, hepatitis, HIV, herpes)

8. Neurologic Injury or disease

9. Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.

10. Alcohol or drug abuse

11. Tobacco use (smoking or chewing)

12. Malnutrition (BMI < 20 kg/m2, hypoalbuminemia, and/or hypotransferrinemia)

13. Obesity (BMI > 30 kg/m2)

14. Low hemoglobin levels (below normal values)

15. Food allergies

16. Taking dietary supplements such as green tea, omega 3 fatty acids, etc.

17. Females

Related Conditions & MeSH terms

• Muscle Synthesis

Intervention

Dietary Supplement:
• Soy Dairy Protein Blend

• Positive Control (Dairy Whey Protein)

Locations

Country	Name	City	State
United States	University of Texas Medical Branch	Galveston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
DuPont Nutrition and Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fractional Synthetic Rate (Muscle Protein Synthesis)	The fractional synthesis rate (FSR) of mixed muscle proteins will be calculated from the incorporation rate of L-[ring-13C6]Phenylalanine into the mixed muscle proteins, and the free-tissue phenylalanine enrichment.	baseline, 3 hrs, 5 hrs
Secondary	Anti-inflammatory and Anti-oxidant Markers	Proteins will be assessed that are markers of oxidative damage and inflammation (NFkB, IL-1, IL-6) and proteolysis (MuRF, MAFBx).	baseline, 3 hrs, 5 hrs
Secondary	Intracellular Signalling Genes and Proteins	Phosphorylation of Mammalian Target of Rapamycin (mTOR) pathway will be measured using Western blot techniques	baseline, 3 hrs, 5 hrs